BPC-157 has driven angiogenesis and tissue repair across preclinical studies — graded by how far the evidence actually reaches.

What the BPC-157 record actually establishes

BPC-157 is a synthetic 15-amino-acid peptide derived from a partial sequence of a protein found in human gastric juice. Across three decades of preclinical work it has been studied for one recurring property: accelerated tissue repair, most consistently linked to angiogenesis — the formation of new blood vessels ^[3]. This site reviews that record and grades it. Findings the animal and cell literature genuinely establishes are marked ESTABLISHED; the tiny human dataset is marked PILOT-ONLY; the gaps are marked NO HUMAN DATA. The grading is the point. A review's job is to say not just what was found, but how far the finding reaches.

The best-characterized mechanism is pro-angiogenic. BPC-157 up-regulates and internalizes the VEGFR2 receptor and activates the downstream VEGFR2-Akt-eNOS (nitric-oxide) pathway ^[3]. That single mechanism is the thread connecting its reported effects on tendon, gut, vasculature, and other tissues, which is why this digest reads the literature through it rather than as a scatter of unrelated results. We treat it as the unifying lens, covered in depth on the BPC-157 angiogenesis research page.

The foundational repair findings are reproducible and specific. In a fully transected rat Achilles tendon, BPC-157 improved biomechanical, functional, and microscopic recovery against untreated controls ^[1]. In rat gastric-ulcer models it cut ulcer area and accelerated healing, with intramuscular delivery outperforming intragastric and an ulcer-formation inhibition ratio reaching roughly 45.7-65.6% at the higher doses ^[4]. These are animal results, measured across multiple endpoints rather than a single proxy — and that specificity is exactly what makes them worth grading rather than hand-waving.

What the record does not contain is just as important to the review. There is no controlled human efficacy trial, no FDA-approved human indication, and no validated human dose ^[12]. The honest summary is a strong, internally consistent preclinical body of work paired with a human dataset still measured in single studies — and a digest worth reading states both halves in the same breath.

BPC-157 as a stable gastric pentadecapeptide

BPC-157 is a stable gastric pentadecapeptide — the descriptor its own authors use, because the molecule is reported stable in human gastric juice. As a BPC-157 peptide it carries the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a molecular formula of C62H98N16O22, and a molecular weight of 1419.53 Da. It is not a hormone and not a growth factor; it is a short peptide that, in animals, is broken down quickly into ordinary amino-acid fragments that re-enter normal metabolism ^[2].

That stability claim is why oral and peroral routes draw interest, and animal ulcer work has dosed the peptide intragastrically ^[4]. But formal human oral pharmacokinetics have never been characterized, so 'stable in the stomach' is an established laboratory property, not a demonstrated route to a clinical effect in people.

Where the human evidence stops

The honest headline is small: as of 2025 reviews, only three small human pilot studies exist ^[12]. A two-person intravenous safety pilot reported no adverse events and no measurable changes in cardiac, hepatic, renal, thyroid, or glucose biomarkers across 10 mg and 20 mg infusions ^[11]. An uncontrolled knee-pain case series reported reduced pain after intra-articular injection ^[10]. A 12-patient intravesical pilot reported symptom resolution in most patients with interstitial cystitis ^[13]. Every one of these is uncontrolled or tiny. None establishes efficacy, and the safety pilot — encouraging as it reads — enrolled exactly two people.

This is the gap a reviewed digest exists to mark. It is tempting, with a decade of consistent rodent data, to round 'works in animals' up to 'works.' The grading on this site refuses that rounding. A finding measured carefully in Wistar rats is a finding about Wistar rats until a controlled human trial says otherwise, and for BPC-157 that trial does not yet exist ^[12]. The mechanism is well characterized in animals; the human chapter has barely begun.

That is not a reason to dismiss the compound and not a reason to oversell it — it is a reason to read the evidence at the resolution it actually has. You can read the full evidence on BPC-157 research findings, study the three human pilot studies in detail, see how BPC-157 doses are expressed in the literature, and review the BPC-157 legal status and 503A category for where regulated access actually stands.

How this digest grades its claims

Five grades run through every page. ESTABLISHED marks what the animal and cell literature genuinely shows — the VEGFR2-Akt-eNOS angiogenesis mechanism ^[3], the transected-Achilles result ^[1], gastric-ulcer cytoprotection ^[4], and the first formal pharmacokinetic characterization ^[2]. PRECLINICAL marks rodent-only or in-vitro mechanism points that have not crossed into humans. PILOT-ONLY marks the three small human studies ^[11][10][13]. NO HUMAN DATA marks the genuine blanks: no controlled efficacy trial, no validated human dose, no human interaction profile ^[12]. REGULATORY marks the access boundaries — covered on BPC-157 FDA 503A compounding status.

One structural caveat sits across the whole record. A large share of the foundational literature comes from a single research group, which newer authors explicitly flag as a replication question ^[12]. A reviewed digest names that, rather than presenting concentrated evidence as if it were broad consensus.